BTIG analyst Thomas Shrader reiterated a Buy rating and $147.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments